Assertio Therapeutics Inc (ASRT) Stock Price, Quote & News

Company Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut sy...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 224 419 7106

Fax: 510 744 8001

Website: www.assertiotx.com

Address:

100 South Saunders Road, Suite 300, Lake Forest, United States

Avedisian Dec. 24 at 9:21 PM

$ASRT The pull forward is specifically for Rolvedon as far as the language of the 10Q says, it doesn't explicitly name Sympazan and other drugs. Also conf call says no material sales for Rolvedon but there will be small amount of sale along with Sympazan and others. So all put together we can expect mid single digit revenue in millions for Q4 and Q1.

0 · Reply

bambus3001 Dec. 24 at 4:58 PM

$ASRT Tief erreicht . Rolvedon wird eine goldene Zukunft für ASRT bringen . Riesig Potenzial über viele Jahre hinaus.

0 · Reply

Luckybreak Dec. 24 at 4:37 PM

$ASRT Market cap below $60 million The ASRT management are the only winners They got their wish granted at expense of long term shareholders holders of ASRT/SPPI The management board says they are working for interest of long term shareholders holders holders . The mother of all law suits will come later . I only wish there is some activist investor that take the present management out . Last 2 weeks is tax loss harvesting /management was not happy with stock sticking above 75 c first they throw / no income for next 2 quarters /that didnt work So final play reverse split /hopefully that gets attention and gets the stock price to below 65c .Some achievement though /we are the humble long term investor /bag holder /we have scars to prove unlike management.My humble opinion Announcement for reverse split at worse time/last 10 days of tax loss harvesting

1 · Reply

haddykatz Dec. 24 at 4:52 AM

$ASRT what’s the chances the new auto-injector is available Q1? Does that require anyone to sign off in the US like fda etc or can it just be phased in and sold?

1 · Reply

Swordfisher Dec. 24 at 3:26 AM

$ASRT Reverse Split…called that one way back. Here’s my next call. That the re-valued price drops 10% to 15% or more w/in the first 3 to 6 months after reverse split. Bagholders get out now & save yourself from further losses after price further drops of your fewer re-valued shares. The R/S does nothing to change the issues of the company. If the company was solid & MM’s were interested, it would have been above $1 long time ago, possibly $2-$5, but guess what, it never did. Do you think Wal-Mart, Costco, could survive if they only had 10 products for sale in their stores for cx’s, NO. Cx’s would shop where they have multiple choices (brands, product, sizes, colours, etc.) How does ASRT survive if all investors see is a company with one product that’s makes up majority of its sales revenues with no guarantee if something happens to that product or if a client goes to a competitor who has more options and better pricing. ASRT is weak because of its overall lack of depth. Bottom line. 🥃

1 · Reply

LearntoRead Dec. 23 at 7:34 PM

$ASRT Hard to believe that on Friday this will only have a $65 million market cap w/Rolvedon sales of more than 65m alone.

1 · Reply

3day Dec. 23 at 6:07 PM

$ASRT scum company

0 · Reply

Chrissytina Dec. 23 at 5:00 PM

$ASRT Of course…Another split 🤦🏼‍♀️ They really need to👇🏻

0 · Reply

D_S Dec. 23 at 4:40 PM

$ASRT The plus about the reverse split is it will highlight the absurd valuation of this stock. It will be approx $10/share after reverse split. It will have $14.4/share in cash ($95M divided by 6.6M shares----though you have to minus off $6/share debt that is due in 1 3/4 years, so $8.4M in true cash/share). It will be doing around $17/share in revenue per year and generating around $2.50/share in cashflow. It won't be hidden in the "penny stock" range anymore either so, hopefully, larger investors will notice the valuation.

1 · Reply

Golfergirl111 Dec. 23 at 4:22 PM

$ASRT There are a lot of calls in the system today for a R/s. Anyone have a clue as to why?

0 · Reply

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

Nov 10, 2025, 6:21 PM EST - 6 weeks ago

Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:13 PM EST - 6 weeks ago

Assertio Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 9:15 AM EDT - 2 months ago

Assertio Announces Leadership Transition

Sep 18, 2025, 5:06 PM EDT - 3 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025

Sep 15, 2025, 9:00 AM EDT - 3 months ago

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV

Sep 10, 2025, 7:30 AM EDT - 3 months ago

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

Sep 3, 2025, 8:15 AM EDT - 4 months ago

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025

Aug 11, 2025, 7:41 PM EDT - 4 months ago

Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:05 PM EDT - 4 months ago

Assertio Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 3:41 PM EDT - 5 months ago

Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors

Aug 5, 2025, 8:30 AM EDT - 5 months ago

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

May 19, 2025, 4:10 PM EDT - 7 months ago

Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025

May 12, 2025, 8:17 PM EDT - 8 months ago

Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 8 months ago

Assertio Reports First Quarter 2025 Financial Results

May 5, 2025, 8:15 AM EDT - 8 months ago

Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 20, 2025, 9:10 AM EDT - 9 months ago

Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

Mar 12, 2025, 6:53 PM EDT - 10 months ago

Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:05 PM EDT - 10 months ago

Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 10 months ago

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

Jan 3, 2025, 4:30 PM EST - 1 year ago

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 17, 2024, 8:30 AM EST - 1 year ago

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

Dec 13, 2024, 8:00 AM EST - 1 year ago

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

Nov 15, 2024, 9:00 AM EST - 1 year ago

Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio

Nov 11, 2024, 6:57 PM EST - 1 year ago

Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:02 PM EST - 1 year ago

Assertio Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 3:41 PM EST - 1 year ago

Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio

Nov 11, 2024, 7:30 AM EST - 1 year ago

Assertio Provides Response to Letter from Short-seller

Nov 8, 2024, 9:00 AM EST - 1 year ago

Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

Sep 11, 2024, 4:18 PM EDT - 1 year ago

Assertio Holdings: Management Change Could Improve Comeback Chances

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

Aug 7, 2024, 9:45 PM EDT - 1 year ago

Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports Second Quarter 2024 Financial Results

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.

Jun 27, 2024, 9:51 AM EDT - 1 year ago

Assertio: An Extremely Asymmetric Bet Skewed To The Upside

Jun 5, 2024, 8:30 AM EDT - 1 year ago

Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024

May 17, 2024, 9:15 AM EDT - 1 year ago

Assertio to Participate in Benchmark Healthcare Conference on May 21-22

May 17, 2024, 7:30 AM EDT - 1 year ago

BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS

May 16, 2024, 9:16 AM EDT - 1 year ago

Assertio to Participate in AGP Healthcare Conference on May 21

May 13, 2024, 5:52 PM EDT - 1 year ago

BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS

May 10, 2024, 3:12 PM EDT - 1 year ago

Assertio to Present at the Citizens JMP Life Sciences Conference in New York City

May 6, 2024, 7:07 PM EDT - 1 year ago

Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports First Quarter 2024 Financial Results

Avedisian Dec. 24 at 9:21 PM

0 · Reply

bambus3001 Dec. 24 at 4:58 PM

$ASRT Tief erreicht . Rolvedon wird eine goldene Zukunft für ASRT bringen . Riesig Potenzial über viele Jahre hinaus.

0 · Reply

Luckybreak Dec. 24 at 4:37 PM

1 · Reply

haddykatz Dec. 24 at 4:52 AM

$ASRT what’s the chances the new auto-injector is available Q1? Does that require anyone to sign off in the US like fda etc or can it just be phased in and sold?

1 · Reply

Swordfisher Dec. 24 at 3:26 AM

1 · Reply

LearntoRead Dec. 23 at 7:34 PM

$ASRT Hard to believe that on Friday this will only have a $65 million market cap w/Rolvedon sales of more than 65m alone.

1 · Reply

3day Dec. 23 at 6:07 PM

$ASRT scum company

0 · Reply

Chrissytina Dec. 23 at 5:00 PM

$ASRT Of course…Another split 🤦🏼‍♀️ They really need to👇🏻

0 · Reply

D_S Dec. 23 at 4:40 PM

1 · Reply

Golfergirl111 Dec. 23 at 4:22 PM

$ASRT There are a lot of calls in the system today for a R/s. Anyone have a clue as to why?

0 · Reply

caddaly Dec. 23 at 4:07 PM

$ASRT still thinking that there will be a point in 2026 where I will say "should have bought more at .60"

1 · Reply

Chrissytina Dec. 23 at 4:07 PM

$ASRT Many times I wonder who’s coming up with this shit! They’ve had a buy 2 for about 2/3 months now 🙄

0 · Reply

Jonnycricket Dec. 23 at 3:57 PM

$ASRT everyone knows that the next 2 quarters will be dismal. that's why the stock has been struggling below 80 cents before the early rs announcement. however ther s more to this price action than meets the eye. legal overhang has been practically cleared, end user sales of R is steady, the distributors who got discounts and extended payment terms are motivated to give preference to Rolvedon over biosimilars and hospitals are being prepped for same day dosing. today we have bargain hunters looking for back fill trades. this will clear out by the end of next week

0 · Reply

Jonnycricket Dec. 23 at 1:14 PM

$ASRT look for a big move in th second half of 26. short term, the board loves to trash the stock so they can reward themselves with cheap options and restricted stock

0 · Reply

Luckybreak Dec. 23 at 12:41 PM

$ASRT Coheres Pharmaceutical sold Udenyca for $558 with upfront payment of $488 and our management has brought the total market cap below $65 million Amazing achievement/Cheers

1 · Reply

Jonnycricket Dec. 23 at 12:34 PM

$ASRT premarket pressure on the ask based on typical post rs announcements. however. they may have something up their sleeves. why announce it at the peak of the tax selling season. perhaps they want to flush out the residual sppi detritice. or they may have a corporate deal in place and this was one of the unwritten agreements -- to get thri4 house in order along with maintaining the nasdaq listing.

0 · Reply

Luckybreak Dec. 23 at 1:56 AM

$ASRT Management is amazing .ASRT has more cash than market cap .They could have easily bought stocks even $10 million which would have kept SP over $ easily .Retail investors have sacrificed dearly and management just survived on the investors hard earned money. This is unbelievable.

0 · Reply

D_S Dec. 23 at 1:51 AM

$ASRT Reverse split....We knew they were going to have to do it after stock didn't hold after Q3. They might as well get it over with in 2025 rather than wait till January. Imo, since they are doing it, it might as well be the 1:15 ratio rather than a lower ratio. It gives us the lowest float possible and makes the stock more volatile. At $10+ in price, it looks more appealing to have on the books for institutions than sub $1 stock. We've already ridden this thing into the mid 50 cents in 2025 so what the heck at this point. Maybe we can get a run the other direction and we all can walk away with some profits (or break even for some). In the end.....The reality is holding this stock right anymore is only about it getting to "fair" value. Small investors and algorithms aren't doing it. The stock above $10 opens the door to institutions buying it cause it's a value play. So I'm not against a reverse split ....Institutions are the only one who are moving this thing to fair value.

1 · Reply

Chuckuk Dec. 22 at 11:13 PM

$ASRT 15 to 1 RS well lets see if we can hold $10

1 · Reply

Polo2024 Dec. 22 at 10:48 PM

$ASRT My only hope now is that they sell the company next year

0 · Reply

Avedisian Dec. 22 at 10:00 PM

$ASRT Boy now we become a super low float stock with about 6m outstanding and almost same for float. Should a positive news come we could skyrocket and a bad news we are toast.

2 · Reply

AStrokeOfLuck Dec. 22 at 9:57 PM

$ASRT

0 · Reply

Market Cap	63.53M
Revenue (ttm)	124.96M
Net Income (ttm)	-21.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-17.27%
Debt to Equity Ratio	0.37

Volume	873,200
Avg Vol	480,956
Day's Range	N/A - N/A
Shares Out	96.25M
Stochastic %K	27%
Beta	0.55
Analysts	Strong Sell
Price Target	$2.73